AUTL
Autolus Therapeutics plc
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
2.41
▼ 0.05 (2.03%)
MARKET · —
Price
Open
2.40
Prev close
2.46
Day high
2.51
Day low
2.40
Volume
2.32M
Market cap
$641.45M
P/E (TTM)
—
52W range
1.18 – 2.58
Trailing performance
Returnvs SPY
1W
+12.09%
+13.5%
1M
+58.55%
+54.8%
3M
+46.06%
+43.0%
6M
+44.31%
+33.2%
YTD
+21.11%
+8.8%
1Y
+39.31%
+19.3%
3Y
-8.71%
-82.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$641.45M
Enterprise value$-122.58M
Revenue (TTM)$1.08M
Gross profit$-26.48M
EBITDA$-68.94M
Net income$-53.28M
EPS (TTM)$-1.06
Free cash flow—
Total cash$217.45M
Total debt$0
Book value / share$5.91
Shares outstanding266.16M
Float33.90M
Short % of float7.99%
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.85
PEG ratio—
Price / sales—
Price / book0.41
EV / revenue-113.66
EV / EBITDA1.78
Gross margin0.00%
Operating margin-6570.75%
Profit margin0.00%
Return on equity-29.62%
Return on assets-22.27%
Debt / equity—
Current ratio11.05
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $75.39M | $10.12M | $1.70M | $6.36M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$287.53M | -$220.67M | -$208.38M | -$148.84M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$287.53M | -$220.67M | -$208.38M | -$148.84M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.19 | -0.15 | +19.6% |
| Mar 2026 | -0.26 | -0.27 | -4.2% |
| Dec 2025 | -0.27 | -0.34 | -28.0% |
| Jun 2025 | -0.24 | -0.18 | +25.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.19 | 6 | $40.53M | +91.2% |
| Next quarter | -0.16 | 6 | $38.35M | +57.9% |
| Current year | -0.79 | 8 | $149.78M | +98.7% |
| Next year | -0.63 | 8 | $192.42M | +28.5% |
Analyst targets & ownership
Mean target$8.73
High target$11.00
Low target$5.00
Implied upside262.03%
Analyst count8
ConsensusSTRONG BUY
Strong buy / Buy1 / 8
Hold0
Sell / Strong sell0 / 0
Held by insiders18.08%
Held by institutions63.42%
Institutions holding101
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
7.12M
Total on file
Moving averages & technicals
SMA 10
2.29
+5.38% from price
SMA 20
2.00
+20.38% from price
SMA 50
1.73
+39.48% from price
SMA 100
1.65
+46.32% from price
SMA 200
1.58
+52.66% from price
EMA 12
2.23
+8.02% from price
EMA 26
2.01
+19.98% from price
EMA 50
1.84
+31.01% from price
RSI (14)
66.6
Neutral
MACD (12,26,9)
0.22
Hist 0.04
ATR (14)
0.20
8.21% of price
Realised vol 30D
95.9%
Annualised
Bollinger upper
2.70
20, 2σ
Bollinger lower
1.30
20, 2σ
50 / 200 cross
Golden
1.73 vs 1.58
Trend bias
Above 200
+52.66%
Risk profile
Beta vs SPY
1.94
More volatile than market
Correlation to SPY
0.31
Loosely linked
Realised vol 30D
95.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-39.5%
Peak to trough
Max drawdown 5Y
-84.5%
Peak to trough
ATR 14
0.20
8.21% of price
Beta (reported)
—
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.13
Call-heavy session
Put / call open interest
0.04
Positioning, not flow
Max pain
1.00
-58.5% from spot
ATM implied vol
71.1%
Nearest strike to spot
Skew (10% OTM)
+60.2%
Puts bid over calls
Call volume
401
Contracts, this expiry
Put volume
52
Contracts, this expiry
Heaviest call OI
1.50
1.06K contracts
Heaviest put OI
2.50
51 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
European Equities Traded in the US as American Depositary Receipts Track Higher in Friday Trading
MT Newswires · 1d ago
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
MT Newswires · 2d ago
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
MT Newswires · 3d ago
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
MT Newswires · 5d ago
European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading
MT Newswires · 8d ago
European Equities Traded in the US Rise in Thursday Trading
MT Newswires · 9d ago
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
MT Newswires · 11d ago
Autolus Therapeutics Q2 Earnings Call Highlights
MarketBeat · 11d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.